Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Hyloris Pharmaceuticals SA is a specialty biopharmaceutical company dedicated to addressing unmet medical needs by innovating, reformulating, and repurposing existing medications. The company leverages established regulatory pathways, such as the FDA’s 505(b)(2) in the U.S. and equivalents elsewhere, to optimize development timelines, reduce costs, and minimize risks for pharmaceuticals with proven safety and efficacy profiles. Hyloris has developed a broad proprietary portfolio of 19 value-added medicines as of late 2024, spanning reformulated and repurposed products alongside high-barrier generics. Key commercial-stage assets include Sotalol IV, an intravenous treatment for atrial fibrillation partnered in the U.S., and Maxigesic® IV, a non-opioid analgesic for post-operative pain available in over 20 countries. Recent additions like HY-083 for idiopathic rhinitis and HY-088 for hypophosphatemia target underserved conditions such as nasal symptoms and mineral deficiencies. Headquartered in Liège, Belgium, and founded in 2012, Hyloris employs around 37 multinational professionals and aims to lead in 505(b)(2)-eligible products, delivering improvements for patients, healthcare providers, and payers through technological expertise and strategic partnerships.
€4.79
+€0.19 (+4.13%)
EOD Jun 23, 2026 · Twelve Data
The business is unprofitable at the operating level (-106.97% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 14.8% YoY. Margins deteriorated 31.7pp alongside, both lines moving the wrong way.
ROIC dropped from -13.46% to -19.63%, capital efficiency is deteriorating. Negative free cash flow of -€8M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€7M
▼ -14.8% YoY
Net Income (TTM)
-€6M
▲ +0.1% YoY
Op. Margin
-106.97%
▼ -31.7pp YoY
ROIC
-19.63%
▼ -6.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€8M
▼ -1.7% YoY
Op. Cash Flow (TTM)
-€6M
▲ +18.6% YoY
Net Debt
-€12M
Net Cash Position
Cash & Equiv.
€14M
3Y CAGR: +100.1%
Continue Research
Hyloris Pharmaceuticals SA (HYL.XBRU)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Hyloris Pharmaceuticals SA scores 43/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Hyloris Pharmaceuticals SA scores 43 out of 100 on Intrinsiqq's quality score, passing 3 of 6 checks, which makes it a mixed business on these measures. Recent fundamentals include a -107.0% operating margin and a -19.6% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh HYL.XBRU's valuation and scores 43/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.